查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球肺部疾病治療市場（疾病類型：哮喘、慢性阻塞性肺病、肺癌、其他肺部疾病）-全球行業分析、規模、份額、增長、趨勢和預測，2022-2031 年
市場調查報告書
商品編碼
1229628

全球肺部疾病治療市場（疾病類型：哮喘、慢性阻塞性肺病、肺癌、其他肺部疾病）-全球行業分析、規模、份額、增長、趨勢和預測，2022-2031 年

Lung Disease Therapeutics Market (Disease Type: Asthma, Chronic Obstructive Pulmonary Disease, Lung Cancer, and Other Lung Diseases) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 205 Pages | 商品交期: 2-10個工作天內

價格

本報告介紹了 2017 年至 2031 年全球肺部疾病治療市場的收入，以 2022 年為基準年，2031 年為預測年。 它還展示了 2022 年至 2031 年全球肺部疾病治療市場的複合年增長率 (CAGR %)。

這份報告是廣泛研究的結果。 在初步研究中，分析師對主要思想領袖、行業領袖和輿論製造者進行了訪談，開展了大量研究工作。 在二次調研中，參考了各大公司的產品文獻、年報、新聞稿、相關文件等，瞭解肺病治療市場。

該報告深入探討了全球肺部疾病治療市場的競爭格局。 已經確定了在全球肺部疾病治療市場運營的主要參與者，並對每家公司進行了不同屬性的分析。 公司概況、財務狀況、近期發展和 SWOT 是本報告中介紹的全球肺病治療市場參與者的屬性。

內容

第一章前言

  • 市場定義和範圍
  • 市場細分
  • 主要研究目標
  • 調查要點

第 2 章假設和研究方法

第 3 章執行摘要：全球肺部疾病治療市場

第 4 章市場概述

  • 介紹
    • 段定義
    • 行業的演變和發展
  • 概覽
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • 2017-2031 年全球肺部疾病治療市場分析與預測

第 5 章關鍵見解

  • 技術進步
  • 製藥管道分析
  • 疾病流行率和發病率（按世界主要國家分類）
  • 區域/全球監管情景
  • COVID-19 影響分析

第6章全球肺部疾病治療市場分析及預測

  • 介紹和定義
  • 重大發現/發展
  • 2017-2031 年按疾病類型劃分的市場價值預測
    • 支氣管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 按疾病類型進行市場吸引力分析

第 7 章肺部疾病治療的全球市場分析和預測：按藥物類別分類

  • 介紹和定義
  • 重大發現/發展
  • 2017-2031 年各藥物類別的市場價值預測
    • 皮質類固醇
    • 支氣管擴張藥
    • 穆科裡奇
    • 抗菌藥
    • 其他
  • 市場吸引力分析：按藥物類別

第 8 章全球肺部疾病治療市場分析及預測（按分銷渠道）

  • 介紹和定義
  • 重大發現/發展
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥房
    • 在線藥店
  • 市場吸引力分析：按分銷渠道

第 9 章肺部疾病治療的全球市場分析和預測：按地區

  • 主要發現
  • 2017-2031 年各地區的市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第10章北美肺部疾病治療市場分析及預測

  • 介紹
    • 主要發現
  • 2017-2031 年按疾病類型劃分的市場價值預測
    • 支氣管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各藥物類別的市場價值預測
    • 皮質類固醇
    • 支氣管擴張藥
    • 穆科裡奇
    • 抗菌藥
    • 其他
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥房
    • 在線藥店
  • 2017-2031 年各個國家/地區的市場價值預測
    • 美國
    • 加拿大
  • 市場吸引力分析
    • 按疾病類型
    • 按治療類別
    • 按分銷渠道
    • 按國家

第 11 章歐洲肺部疾病治療市場分析和預測

  • 介紹
    • 主要發現
  • 2017-2031 年按疾病類型劃分的市場價值預測
    • 支氣管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各藥物類別的市場價值預測
    • 皮質類固醇
    • 支氣管擴張藥
    • 穆科裡奇
    • 抗菌藥物
    • 其他
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥房
    • 在線藥店
  • 2017-2031 年按國家/地區劃分的市場價值預測
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 市場吸引力分析
    • 按疾病類型
    • 按治療類別
    • 按分銷渠道
    • 按國家/地區

第十二章亞太地區肺部疾病治療市場分析及預測

  • 介紹
    • 主要發現
  • 2017-2031 年按疾病類型劃分的市場價值預測
    • 支氣管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各藥物類別的市場價值預測
    • 皮質類固醇
    • 支氣管擴張劑
    • 穆科裡奇
    • 抗菌藥
    • 其他
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥房
    • 在線藥店
  • 2017-2031 年按國家/地區劃分的市場價值預測
    • 中國
    • 日本
    • 印度
    • 澳大利亞和新西蘭
    • 其他亞太地區
  • 市場吸引力分析
    • 按疾病類型
    • 按治療類別
    • 按分銷渠道
    • 按國家/地區

第 13 章拉丁美洲肺部疾病治療市場分析和預測

  • 介紹
    • 主要發現
  • 2017-2031 年按疾病類型劃分的市場價值預測
    • 支氣管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各藥物類別的市場價值預測
    • 皮質類固醇
    • 支氣管擴張藥
    • 穆科裡奇
    • 抗菌藥
    • 其他
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥房
    • 在線藥店
  • 2017-2031 年按國家/地區劃分的市場價值預測
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 市場吸引力分析
    • 按疾病類型
    • 按治療類別
    • 按分銷渠道
    • 按國家/地區

第14章中東和非洲肺部疾病治療市場分析及預測

  • 介紹
    • 主要發現
  • 2017-2031 年按疾病類型劃分的市場價值預測
    • 支氣管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各藥物類別的市場價值預測
    • 皮質類固醇
    • 支氣管擴張藥
    • 穆科裡奇
    • 抗菌藥物
    • 其他
  • 2017-2031 年各分銷渠道的市場價值預測
    • 醫院藥房
    • 零售藥房
    • 在線藥店
  • 2017-2031 年按國家/地區劃分的市場價值預測
    • 海灣合作委員會國家
    • 南非
    • 其餘中東和非洲地區
  • 市場吸引力分析
    • 按疾病類型
    • 按治療類別
    • 按分銷渠道
    • 按國家/地區

第15章競爭格局

  • 市場參與者 - 競爭矩陣（按公司層級和公司規模）
  • 市場份額分析：按公司分類（2021 年）
  • 公司簡介
    • GSK
    • AstraZeneca
    • Boehringer Ingelheim
    • Novartis
    • Vertex Pharmaceuticals
    • F. Hoffman La Roche
    • Teva Pharmaceuticals
    • Cipla
    • Liminal Biosciences
    • Fibrogen
    • PharmAkea Therapeutics
    • IQVIA
Product Code: TMRGL85362

The report provides revenue of the global lung disease therapeutics market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung disease therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung disease therapeutics market.

The report delves into the competitive landscape of the global lung disease therapeutics market. Key players operating in the global lung disease therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global lung disease therapeutics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Lung Disease Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Lung Disease Therapeutics Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Drug Pipeline Analysis
  • 5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.4. Regulatory Scenario by Region/Globally
  • 5.5. COVID-19 Impact Analysis

6. Global Lung Disease Therapeutics Market Analysis and Forecast, by Disease Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Disease Type, 2017-2031
    • 6.3.1. Asthma
    • 6.3.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 6.3.3. Lung Cancer
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Disease Type

7. Global Lung Disease Therapeutics Market Analysis and Forecast, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Drug Class, 2017-2031
    • 7.3.1. Corticosteroids
    • 7.3.2. Bronchodilator Medications
    • 7.3.3. Mucolytics
    • 7.3.4. Antimicrobial Medications
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Drug Class

8. Global Lung Disease Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Lung Disease Therapeutics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Lung Disease Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Disease Type, 2017-2031
    • 10.2.1. Asthma
    • 10.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 10.2.3. Lung Cancer
    • 10.2.4. Others
  • 10.3. Market Value Forecast, by Drug Class, 2017-2031
    • 10.3.1. Corticosteroids
    • 10.3.2. Bronchodilator Medications
    • 10.3.3. Mucolytics
    • 10.3.4. Antimicrobial Medications
    • 10.3.5. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Disease Type
    • 10.6.2. By Drug Class
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Lung Disease Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Disease Type, 2017-2031
    • 11.2.1. Asthma
    • 11.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 11.2.3. Lung Cancer
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Drug Class, 2017-2031
    • 11.3.1. Corticosteroids
    • 11.3.2. Bronchodilator Medications
    • 11.3.3. Mucolytics
    • 11.3.4. Antimicrobial Medications
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Disease Type
    • 11.6.2. By Drug Class
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Lung Disease Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Disease Type, 2017-2031
    • 12.2.1. Asthma
    • 12.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 12.2.3. Lung Cancer
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Drug Class, 2017-2031
    • 12.3.1. Corticosteroids
    • 12.3.2. Bronchodilator Medications
    • 12.3.3. Mucolytics
    • 12.3.4. Antimicrobial Medications
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Disease Type
    • 12.6.2. By Drug Class
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Lung Disease Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Disease Type, 2017-2031
    • 13.2.1. Asthma
    • 13.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 13.2.3. Lung Cancer
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Drug Class, 2017-2031
    • 13.3.1. Corticosteroids
    • 13.3.2. Bronchodilator Medications
    • 13.3.3. Mucolytics
    • 13.3.4. Antimicrobial Medications
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Disease Type
    • 13.6.2. By Drug Class
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Lung Disease Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Disease Type, 2017-2031
    • 14.2.1. Asthma
    • 14.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 14.2.3. Lung Cancer
    • 14.2.4. Others
  • 14.3. Market Value Forecast, by Drug Class, 2017-2031
    • 14.3.1. Corticosteroids
    • 14.3.2. Bronchodilator Medications
    • 14.3.3. Mucolytics
    • 14.3.4. Antimicrobial Medications
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of MEA
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Disease Type
    • 14.6.2. By Drug Class
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. GSK
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Disease Type Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. AstraZeneca
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Disease Type Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Boehringer Ingelheim
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Disease Type Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Novartis
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Disease Type Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Vertex Pharmaceuticals
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Disease Type Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. F. Hoffman La Roche
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Disease Type Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Teva Pharmaceuticals
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Disease Type Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Cipla
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Disease Type Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Liminal Biosciences
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Disease Type Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Fibrogen
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Disease Type Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. PharmAkea Therapeutics
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Disease Type Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. IQVIA
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Disease Type Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 02: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 07: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 08: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 11: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 15: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 16: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 19: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 23: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 24: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Lung Disease Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
  • Figure 02: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Disease Type, 2021
  • Figure 03: Global Lung Disease Therapeutics Market Value Share, by Disease Type, 2021
  • Figure 04: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Drug Class, 2021
  • Figure 05: Global Lung Disease Therapeutics Market Value Share, by Drug Class, 2021
  • Figure 06: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2021
  • Figure 07: Global Lung Disease Therapeutics Market Value Share, by Distribution Channel, 2021
  • Figure 08: Global Lung Disease Therapeutics Market Value Share, by Region, 2021
  • Figure 09: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 11: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 12: Global Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 13: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 14: Global Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 15: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 16: Global Lung Disease Therapeutics Market Value Share Analysis, by Region, 2017 and 2031
  • Figure 17: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 20: North America Lung Disease Therapeutics Market Value Share Analysis, by Country, 2017 and 2031
  • Figure 21: North America Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 22: North America Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 23: North America Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 24: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 25: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 26: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 27: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 29: Europe Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 30: Europe Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 31: Europe Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 32: Europe Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 33: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 34: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 35: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 36: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 38: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 39: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 40: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 41: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 42: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 43: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 44: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 45: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 47: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 48: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 49: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 50: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 51: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 52: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 53: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 54: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 56: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 57: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 58: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 59: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 60: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 61: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 62: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031